Intellectual Property India Publishes Patent Application for Substituted Heterocyclic Compounds And Their Derivatives As P300 Selective Degraders

MUMBAI, India, Nov. 2 -- Intellectual Property India has published a patent application (202647127882 A) filed by Aurigene Oncology Limited on October 27, 2026, for Substituted Heterocyclic Compounds And Their Derivatives As P300 Selective Degraders.

Inventors include Abbineni, Chandrasekhar; Samajdar, Susanta; and Talluri, Krishna Chaitanya.

The application for the patent was published on October 30, 2026, under issue no. 44/2026.

Abstract: The present disclosure provides substituted heterocyclic compounds of formula (I), which are therapeutically useful as p300 degraders. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the p300 degradation. Compounds of the present disclosure are...